LKFT · Lakefront Biotherapeutics American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow LKFT by emailGet an email when LKFT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LKFT, unsubscribe in one click. Privacy
📣 What LKFT Says Is Next
in 2027 · “Gamgertamig is currently in Phase 2 studies and is expected to enter registrational studies in 2027.”
Company press release, Aug 25, 2026 · SEC filing
in 2027 · “The program is currently under an open Investigational New Drug (IND) in the U.S. and is expected to enter registrational studies in 2027.”
Company press release, Mar 31, 2026 · SEC filing
in 2027 · “OM336 is under an open IND in the U.S. and is expected to enter registrational studies in 2027.”
Company press release, Mar 24, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full LKFT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LKFT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.